Table 1 Epigenome-wide significant probes for PD identified in SGPD.

From: Analysis of DNA methylation associates the cystine–glutamate antiporter SLC7A11 with risk of Parkinson’s disease

Chr

Probe

BP

Gene

Cohort

bMOA

seMOA

pMOA

bMOM

seMOM

pMOM

8

cg16001422

145022842

PLEC

SGPD

−3.05

0.54

2.3  ×  10−08

−1.04

0.60

8.3  ×  10−02

PEG

−0.44

0.96

0.65

−8.1  ×  10−03

0.91

0.99

10

cg26033520

74004071

ASCC1

SGPD

−1.55

0.29

1.3  ×  10−07

−1.09

0.29

1.9  ×  10−04

PEG

−1.17

0.56

0.04

−0.77

0.53

0.15

  1. Results are shown for the two epigenome-wide significant probes in the MOA MWAS of SGPD, together with results for these probes from the MOMENT (MOM) MWAS of SGPD and the MOA and MOMENT MWAS’s of the PEG replication data. Effect sizes (b) and standard errors (se) from OSCA are not standardized.
Back to article page